Shortly after announcing positive Phase 2a results for its glycopyrrolate inhalation solution, Elevation Pharmaceuticals, announced that it has appointed Jaisim Shah as Senior Vice President and Chief Business Officer and Pravin Soni as Senior Vice President and Chief Technical Officer. Both positions are newly created.
“Mr. Shah and Dr. Soni bring strong commercial and technical leadership skills to Elevation. Their addition to the Elevation leadership team significantly enhances our ability to develop and optimally position in the marketplace new inhaled drug therapies that meet significant unmet clinical needs,” commented Elevation President and CEO Bill Gerhart.
In response to his appointment, Shah said, “Considering the positive Phase 2a trial results announced today and the draw-down of the $17 million tranche of its Series A financing, Elevation is poised to accelerate the development of its lead candidate and begin development of its pipeline. I am very pleased to be joining the Company at this exciting stage, and I look forward to working with the rest of the management team to help realize Elevation’s full potential.”
Soni, who will be responsible for device and drug development activities was previously Vice President of Product Research and Development for Alexza Pharmaceuticals, where he led development of the Staccato inhaler.
Read the Elevation press release.
